Inhibition of the activation of Hageman factor (factor XII) by peripheral blood cells.
AUTOR(ES)
Ratnoff, O D
RESUMO
Suspensions of peripheral blood mononuclear cells (PBMC), monocytes, T or B lymphocytes, platelets or granulocytes, and cell-depleted supernatant fluids of these suspensions inhibited activation of Hageman factor (HF, Factor XII) by ellagic acid, a property not shared by erythrocytes. PBMC also inhibited HF activation by glass or sulfatides. Contaminating platelets may have contributed to inhibition by PBMC. Elaboration of agents inhibiting HF activation required metabolically active cells. The inhibitor(s) in PBMC supernates were not identified with known agents, but had properties of a nonenzymatic protein. PBMC supernates did not contain fibrinogen, nor alter the thrombin, prothrombin, or partial thromboplastin times of normal plasma, amidolysis by activated plasma thromboplastin antecedent (Factor XIa) or activated Stuart factor (Factor Xa) or esterolysis by C1 (C1 esterase); they inhibited plasmin minimally. These experiments suggest that peripheral blood cells may impede intravascular coagulation. Whether this property helps maintain the fluidity of blood is unclear.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=442363Documentos Relacionados
- The activation of plasminogen by Hageman factor (Factor XII) and Hageman factor fragments.
- Inhibition of the activation of Hageman factor (factor XII) by complement subcomponent C1q.
- Inhibition of the activation of Hageman factor (factor XII) by human vascular endothelial cell culture supernates.
- The Secondary Structure of Human Hageman Factor (Factor XII) and its Alteration by Activating Agents
- Role of surface in surface-dependent activation of Hageman factor (blood coagulation Factor XII)